Author + information
- Alexander Christian Falkentoft,
- Rasmus Rørth,
- Dan Eik Høfsten,
- Kasper Iversen,
- Thomas Engstrøm,
- Henning Kelbæk,
- Lene Holmvang,
- Martin Frydland,
- Klaus Kofoed,
- Jens Peter Goetze,
- Christian Torp-Pedersen and
- Lars Køber
Background: Midregional proadrenomedullin (MR-proADM) has demonstrated promising prognostic potential in myocardial infarction (MI) and heart failure (HF). Yet admission MR-proADM has not been investigated in a large cohort of patients with ST-segment elevation MI (STEMI). We examined MR-proADM in the Third Danish Study of Optimal Acute Treatment of Patients with STEMI.
Methods: MR-proADM was measured in blood samples obtained immediately upon arrival in the catheterization laboratory before primary percutaneous coronary intervention. We assessed the association between MR-pro-ADM and all-cause mortality, 30-days mortality and hospital admission for HF using Cox proportional hazard models adjusted for age, gender, heart rate and 8 other established risk factors.
Results: In total 1122 patients were included (median age, 62 years [interquartile range 53-70]; 75.6 % men). During a median follow-up of 1075 days (interquartile range 886-1271), 80 (7.1 %) died, 23 (2.1 %) died within 30 days and 38 (3.4 %) were admitted for HF. All-cause mortality increased significantly between quartiles (figure). A doubling of MR-proADM was, in adjusted models, associated with an increased risk of long-term mortality (hazard ratio 2.94, 95% confidence interval [CI] 1.93-4.46), mortality within 30 days (hazard ratio 2.80, 95% CI 1.32-5.94) and admission for HF (hazard ratio 3.00, 95% CI 1.62-5.57).
Conclusions: Admission MR-proADM is associated with increased short- and long-term mortality and HF after STEMI.
Moderated Poster Contributions
Acute and Stable Ischemic Heart Disease Moderated Poster Theater, Poster Hall, Hall C
Friday, March 17, 2017, 11:00 a.m.-11:10 a.m.
Session Title: Post-CAD/MI: Making Tough Predictions About the Future
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1138M-11
- 2017 American College of Cardiology Foundation